A
This company focuses on the convergence of physical and digital worlds through bio-digital twins and ambient computing. They integrate AI agents and cybersecurity mesh to provide context-aware, proactive enterprise solutions. The firm also emphasizes sustainability by embedding green software engineering principles into technology design and operations.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Athernal Bio develops targeted immunotherapies designed to treat high-risk clonal haematopoiesis, a precursor condition to blood cancer. The company's approach focuses on training the immune system to detect and eliminate mutated hematopoietic stem cells before malignancy develops. This strategy aims to provide the first therapeutic intervention for this prevalent condition, reducing the risk of acute myeloid leukemia and other age-related diseases.